- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05890053
To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia
A 52-week, Open Phase III Study Evaluating the Long-term Safety and Efficacy of HSK16149 Capsules in Chinese Patients With Peripheral Neuralgia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100034
- Peking University First Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who completed double-blind treatment and safety follow-up in HSK16149-201/301.
- Able to understand and voluntarily sign informed consent.
Exclusion Criteria:
- Medication compliance was < 80% in double-blind studies.
- In double-blind study, EOT visit (V10) eGFR< 60 mL/min//1.73m2
- Significant safety concerns or adverse events that did not recover before taking the drug in this study arose in the double-blind study.
- Hepatitis B Surface antigen (HBsAg) positive or hepatitis C virus antibody (HCV Ab) positive during screening [further hepatitis B virus deoxyribonucleic acid (HBV DNA) titer detection or hepatitis C virus ribonucleic acid (HCV RNA) detection (beyond the detection limit of assay need to be excluded)], human immunodeficiency virus antibody (HIV) Ab) positive, serum antibody to treponema pallidum (TP Ab) positive (further test for treponema pallidum titer, if positive, excluded).
- Women who are pregnant, planning to become pregnant during the study, or breastfeeding; Participants were not expected to use reliable contraceptive methods (including condoms, spermicides, or intrauterine devices) for 28 days after signing up for the ICF or planning to use progester-containing contraceptives during this period.
- The researcher judged that the study could not be completed according to the scheme or that it was difficult to participate in the study due to safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSK16149 40mg BID
HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.
|
HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the long-term safety of HSK16149 capsules in Chinese patients with peripheral neuralgia.
Time Frame: From week 1 to week 53
|
Safety assessment variables included AE, ECG, laboratory test values, height and weight, physical examination, and vital signs.
Safety data will be summarized by aggregate in SS and all subjects will be listed.
Overall description of all AE occurred in subjects by total, and summary of cases, cases and percentage.
Clinical judgments of laboratory indicators before and after drug administration (according to the range of normal values or the investigator's judgment of clinical significance) were summarized in the form of crosstabs, and the number and percentage of cases were calculated.
|
From week 1 to week 53
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in SF-MPQ scores from baseline before and after treatment to evaluate the long-term effectiveness of HSK16149.
Time Frame: From week 1 to week 53
|
Based on FAS, descriptive statistical analysis and mapping analysis were performed on the mean values of VAS, PRI and PPI scores and the mean changes from baseline of each visiting point, to compare whether there were statistical differences before and after treatment. Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - fifteen descriptors of pain intensity, on a scale of 0 (none) to 3 (severe) Part 2 - a visual analog scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain) |
From week 1 to week 53
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSK16149-303
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Neuropathic Pain
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
AptinyxWorldwide Clinical TrialsCompletedDiabetic Peripheral Neuropathic PainUnited States
-
Riphah International UniversityCompletedDiabetic Peripheral Neuropathic PainPakistan
-
University Hospital, Clermont-FerrandRecruitingPeripheral Neuropathic PainFrance
-
Yuhan CorporationCompletedPeripheral Neuropathic PainKorea, Republic of
-
Zhejiang Chinese Medical UniversityThe First Affiliated Hospital of Zhejiang Chinese Medical University; The Second...Not yet recruitingDiabetic Peripheral Neuropathic PainChina
-
Pure GreenUnknownDiabetic Peripheral Neuropathic PainUnited States
-
Viatris KoreaRecruitingPeripheral Neuropathic PainKorea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPeripheral Neuropathic Pain
-
AstraZenecaCompletedNociceptive Pain | Peripheral Neuropathic PainUnited Kingdom
Clinical Trials on HSK16149 40mg BID
-
Haisco Pharmaceutical Group Co., Ltd.CompletedPostherpetic NeuralgiaChina
-
Haisco Pharmaceutical Group Co., Ltd.UnknownDiabetic Peripheral Neuropathic PainChina
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Haisco Pharmaceutical Group Co., Ltd.CompletedHerpetic NeuralgiaChina
-
Haisco Pharmaceutical Group Co., Ltd.CompletedRenal ImpairmentChina
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingDiabetic Peripheral Neuropathic PainChina
-
Haisco Pharmaceutical Group Co., Ltd.The Fourth Hospital of Hebei Medical UniversityRecruitingDiabetic Neuropathies | Diabetic Neuropathy PeripheralChina
-
Daewoong Pharmaceutical Co. LTD.CompletedErosive EsophagitisKorea, Republic of
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityCompleted
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male SubjectsKorea, Republic of